Last reviewed · How we verify
NCT03810768: MIRACLE I
Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness
trial in Metabolomics in 20 participants. Currently enrolling.
1 November 2026
Quick facts
| Lead sponsor | Technical University of Munich |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 2 September 2022 |
| Primary completion | 1 November 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 3 locations across Austria, Germany |
Conditions studied
- Metabolomics — all drugs for Metabolomics →
- Critical Care — all drugs for Critical Care →
- Critical Illness — all drugs for Critical Illness →
- Critical Illness Myopathy — all drugs for Critical Illness Myopathy →
Sponsor
Technical University of Munich
Who can join
18 and older, any sex, with Metabolomics or Critical Care. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this mono-center pilot trial, surgical patients who are at high risk to be admitted to intensive care will be screened and asked for participation. We are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing. Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03810768
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolomics
Currently open trials in the same condition.
- NCT07392905 — Food Intake-Related Brain and Metabolic Responses in Obesity · NA · recruiting
- NCT06951386 — The Impact of Daily Intake of Short-chain Fatty Acids on Cardiometabolic Risk Factors in Individuals at Risk for Metabol · NA · recruiting
- NCT06614660 — Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer · active not recruiting
- NCT06073470 — Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With A · recruiting
- NCT06843707 — Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics. · recruiting
Other Technical University of Munich trials
Trials by the same sponsor.
- NCT07519811 — LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) · NA · recruiting
- NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
- NCT07077005 — Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy · NA · recruiting
- NCT07212699 — Development of an Outcome Score for Patients With Knee Osteoarthritis and Knee Joint Endoprosthesis Using an App · NA · recruiting
- NCT06823271 — Haemodynamics and Ventricular Arrhythmias During Exercise in Patients With Arrhythmogenic Cardiomyopathy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03810768 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Technical University of Munich
- Last refreshed: 3 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03810768.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing